Profil bibliographique

Mona Tomaschko

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

98Publications signalées

232Citations signalées

1Affiliations récentes

Les institutions déclarées

The Francis Crick Institute

Les domaines associés

Synthesis and Biological EvaluationSynthesis and biological activityCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosisCancer, Stress, Anesthesia, and Immune Response

Les publications récentes

Accès ouvert 2026 other OpenAlex

Figure 5 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones

Mona Tomaschko, KangBo Ng, Christopher E. G. Moore, Claire E. Pillsbury et autres

Treatments modulate the immune TME and increase inflammation. A, Schematic: Mixed subcutaneous tumors (BFP KRAS G12C cells plus 0.2% Luc-eGFP KRAS G12D cells) were treated for 6 days with RMC-4998 (G12Ci) ± RMC-4550 (SHP2i) or anti–PD-1 (aPD-1). Flow cytometry of tumors and …

0 citations

Accès ouvert 2026 other OpenAlex

Table S4 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones

Mona Tomaschko, KangBo Ng, Christopher E. G. Moore, Claire E. Pillsbury et autres

Spectral flow cytometry staining panel for analysis of Emv2-specific T cells

0 citations

Accès ouvert 2026 other OpenAlex

Data from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones

Mona Tomaschko, KangBo Ng, Christopher E. G. Moore, Claire E. Pillsbury et autres

Abstract The clinical benefit of therapies targeting the KRAS G12C mutation is substantially limited by the development of resistance through multiple mechanisms. Therefore, to achieve lasting benefit with these therapies, effective strategies to tackle the evolution of drug resistance are required. To …

0 citations

Accès ouvert 2026 other OpenAlex

Figure S11 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones

Mona Tomaschko, KangBo Ng, Christopher E. G. Moore, Claire E. Pillsbury et autres

TME phenotyping via spectral flow cytometry

0 citations

Accès ouvert 2026 other OpenAlex

Figure S4 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones

Mona Tomaschko, KangBo Ng, Christopher E. G. Moore, Claire E. Pillsbury et autres

Characterisation of mixed KPAR 1.3 tumors

0 citations

Accès ouvert 2026 other OpenAlex

Figure S1 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones

Mona Tomaschko, KangBo Ng, Christopher E. G. Moore, Claire E. Pillsbury et autres

Spectral flow cytometry gating strategy

0 citations

Accès ouvert 2026 other OpenAlex

Figure S3 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones

Mona Tomaschko, KangBo Ng, Christopher E. G. Moore, Claire E. Pillsbury et autres

Generation of reporter-transduced KPAR1.3 cell lines

0 citations

Accès ouvert 2026 other OpenAlex

Figure 7 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones

Mona Tomaschko, KangBo Ng, Christopher E. G. Moore, Claire E. Pillsbury et autres

Immune rejection of mechanistically distinct G12Ci-resistant tumor subpopulations. A, Viability assays of KPAR.E2 cells and parental KPAR1.3 KRAS G12C cells (parent G12C). Cells were treated for 72 hours with the G12Cis adagrasib and RMC-4998. Mean ± SEM; n = 3. B, Western …

0 citations

Accès ouvert 2026 other OpenAlex

Figure 6 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones

Mona Tomaschko, KangBo Ng, Christopher E. G. Moore, Claire E. Pillsbury et autres

Adaptive immunity is required for durable responses. A, Experimental design for B and C. KRAS G12C KPAR1.3 wild-type (WT) or Emv2-KO tumors were treated for 6 days with RMC-4998 (100 mg/kg; G12Ci) ± RMC-4550 (SHP2i) or anti–PD-1 (aPD-1). B, Fraction of Emv2-specific …

0 citations

Accès ouvert 2026 other OpenAlex

Table S2 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones

Mona Tomaschko, KangBo Ng, Christopher E. G. Moore, Claire E. Pillsbury et autres

Real-time PCR primers

0 citations

Accès ouvert 2026 other OpenAlex

Figure S7 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones

Mona Tomaschko, KangBo Ng, Christopher E. G. Moore, Claire E. Pillsbury et autres

Outline of image analysis pipeline

0 citations

Accès ouvert 2026 other OpenAlex

Table S6 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones

Mona Tomaschko, KangBo Ng, Christopher E. G. Moore, Claire E. Pillsbury et autres

GSEA significant targets across all treatment groups

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.